Personalized medicines could be manufactured with 3D printing technology

NewsGuard 100/100 Score

Customized medicines could one day be manufactured to patients’ individual needs, with University of East Anglia (UEA) researchers investigating technology to 3D ‘print’ pills.

Personalized medicines could be manufactured with 3D printing technology
Image Credit: University of East Anglia

The team, including Dr Andy Gleadall and Prof Richard Bibb at Loughborough University, identified a new additive manufacturing method to allow the 3D printing of medicine in highly porous structures, which can be used to regulate the rate of drug release from the medicine to the body when taken orally.

Dr Sheng Qi, a Reader in Pharmaceutics at UEA’s School of Pharmacy, led the research. The project findings, ‘Effects of porosity on drug release kinetics of swellable and erodible porous pharmaceutical solid dosage forms fabricated by hot melt droplet deposition 3D printing’, are published today in the International Journal of Pharmaceutics.

Currently our medicines are manufactured in 'one-size-fits-all' fashion. Personalized medicine uses new manufacturing technology to produce pills that have the accurate dose and drug combinations tailored to individual patients. This would allow the patients to get maximal drug benefit with minimal side effects. Such treatment approaches can particularly benefit elderly patients who often have to take many different types of medicines per day, and patients with complicated conditions such as cancer, mental illness and inflammatory bowel disease.”

Dr Sheng Qi, Reader in Pharmaceutics, UEA’s School of Pharmacy

The team’s work, Dr Qi said, is building the foundation for the technology needed in future to produce personalized medicine at the point-of-care. She said 3D printing has the unique ability to produce porous pharmaceutical solid dosage forms on-demand.

Pharmaceutical 3D printing research is a new research field that has rapidly developed in the past five years. Most commonly used 3D printing methods require the drug being processed into spaghetti-like filaments prior to 3D printing.

The team investigated a newly developed 3D printing method that can rapidly produce porous pharmaceutical tablets without the use of filaments. The results revealed that by changing the size of the pores, the speed of a drug escaping from the tablet into the body can be regulated.

Further research will be required in order to use the porosity to tailor the dose and dosing frequency (i.e. once daily or twice daily) of medicine to each patient’s needs, and use this principle to build multiple medicines into a single daily poly-pill for patients who are on a complex medicine regiment.

The paper, ‘Effects of porosity on drug release kinetics of swellable and erodible porous pharmaceutical solid dosage forms fabricated by hot melt droplet deposition 3D printing’, was published on 3 May 2021 in the International Journal of Pharmaceutics.

Source:
Journal reference:

Zhang, B., et al. (2021) Effects of porosity on drug release kinetics of swellable and erodible porous pharmaceutical solid dosage forms fabricated by hot melt droplet deposition 3D printing. International Journal of Pharmaceutics. doi.org/10.1016/j.ijpharm.2021.120626.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Chatbots for mental health pose new challenges for US regulatory framework